Menu
Back to Journals » Cancer Management and Research » Volume 14
LncRNA FOXD3-AS1 Promotes Tumorigenesis of Glioma via Targeting miR-128-3p/SZRD1 Axis [Retraction]
Li Z, Li M, Xia P, Wang L, Lu Z. Cancer Manag Res. 2021;13:9037–9048.
The Editor and Publisher of Cancer Management and Research wish to retract the published article. Concerns were raised regarding alleged image duplication in Figure 3 and Figure 7. Specifically:
- Figure 3D, panel HS683 si-NC appears to have been duplicated with Figure 7D, panel HS683 miR-128-3p mimic+OE-SZRD1.
- Figure 3D, panel HS683 si-FOXD3-AS1 appears to have been duplicated with Figure 7D, panel HS683 miR-128-3p mimic.
- Figure 3D, panel HS683 miR-128-3p inhibitor appears to have been duplicated with Figure 7D, panel HS683 OE-SZRD1.
- Figure 3F, panel U251 Control appears to have been duplicated with Figure 7F, panel U251 Control.
- Figure 3F, panel U251 miR-128-3p inhibitor appears to have been duplicated with Figure 7F, panel U251 OE-SZRD1.
The authors responded to our queries but could not provide a satisfactory explanation for the alleged duplication or provide adequate raw data for their study. The findings of the study were deemed invalid and the Editor requested for the article to be retracted.
Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
© 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.